Haemodialysis and peritoneal dialysis: Metabolic alterations and nutritional status

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 2, Issue 4, 1999, Pages 329-333

  Cano, Noël ^a  

^a Hôpital Privé Résidence du Parc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NITROGEN;

ENERGY METABOLISM; HUMAN; METABOLISM; NUTRITIONAL REQUIREMENT; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW;

ENERGY METABOLISM; HUMANS; METABOLISM; NITROGEN; NUTRITIONAL REQUIREMENTS; NUTRITIONAL STATUS; PERITONEAL DIALYSIS; PROGNOSIS; RENAL DIALYSIS;

EID: 0033162629     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-199907000-00014     Document Type: Article

References (65)

1. Cano N, Fernandez JP, Lacombe P, Lankester M, Pascal S, Defayolle M, et al. Statistical selection of nutritional parameters in hemodialyzed patients. Kidney Int 1987; 32 (suppl. 22):S178-180.
2. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993; 329:1001-1006.
3. Avram MM, Mittman N, Bonomini L, Chattopadhyay J, Fein P. Markers for survival in dialysis: a seven-year prospective study. Am J Kidney Dis 1995; 26:209-219.
4. Cano N, Leverve XM. Influence of chronic liver disease and chronic renal failure on nutrient metabolism and undernutrition. Nutrition 1997; 13:381-383.
5. Bergström J, Wang T, Lindholm B. Factors contributing to catabolism in endstage renal disease patients. Miner Electrolyte Metab 1998; 24:92-101.
6. Mitch WE, Maroni BJ. Factors causing malnutrition in patients with chronic uremia. Am J Kidney Dis 1999; 33:176-179. This is a clear review of the main mechanisms of malnutrition in dialysis patients.
7. Mitch WE, Medina R, Grieber S, May RC, England BK, Price SR, et al. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 1994; 93:2127-2133.
8. Lim VS, Yarasheski E, Flanigan MJ. The effect of uremia, acidosis, and dialysis treatment on protein metabolism: a longitudinal leucine kinetic study. Nephrol Dial Transplant 1998; 13:1723-1730. This is an elegant longitudinal study of the effect of the correction of acidosis on protein metabolism.
9. Graham KA, Reaich D, Channon SM, Downie S, Goodship THJ. Correction of acidosis in hemodialysis patients decreases whole-body protein degradation. J Am Soc Nephrol 1997; 8: 632-637.
10. Graham KA, Reaich D, Channon SM, Downie S, Gilmour E, Passlick-Deetjen J, et al. Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int 1996; 49:1395-1400.
11. Uribarri J, Zia M, Mahmood J, Marcus RA, Oh MS. Acid production in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9:114-120.
12. Boon L, Blommart PJE, Meijer AJ, Lamers WH, Schoolwerth AC. Acute acidosis inhibits liver amino acid transport: no primary role for the ornithine cycle in acid-base homeostasis. Am J Physiol 1994; 267:F1015-1020.
13. Cano N, Catelloni F, Fontaine E, Novaretti R, Reynier JP, Leverve XM. Isolated rat hepatocyte metabolism is affected by chronic renal failure. Kidney Int 1995; 47:1522-1527.
14. Ballmer PE, McNurlan MA, Hulter HN, Anderson SE, Garlick PJ, Krapf R. Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 1995; 95:39-45.
15. Movilli E, Bossini N, Viola BF, Camerini C, Cancarini GC, Feller P, et al. Evidence for an independent role of metabolic acidosis on nutritional status in haemodialysis patients. Nephrol Dial Transplant 1998; 13:674-678.
16. Brady JP, Hasbargen JA. Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis 1998; 31:35-40.
17. Graham KA, Hoenich NA, Tarbit M, Ward MK, Goodship THJ. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 1997; 8:627-631.
18. Mak RHK. Effect of metabolic acidosis on insulin action and secretion in uremia. Kidney Int 1998; 54:603-607.
19. Kuemmerle N, Krieg RJJ, Latta K, Challa A, Hanna JD, Chan JC. Growth hormone and insulin-like growth factor in non-uremic acidosis and uremic acidosis. Kidney Int 1997; 51 (Suppl. 58):S102-105.
20. Brüngger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in humans. Kidney Int 1997; 51:216-221.
21. Brüngger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on thyroid hormone homeostasis in humans. Am J Physiol 1997; 275:F648-653.
22. Mak RH. Effect of recombinant human erythropoietin on insulin, amino acid, and lipid metabolism in uremia. J Pediatr 1996; 129:97-104.
23. Mak RH. Metabolic effects of erythropoietin in patients on hemodialysis. Pediatr Nephrol 1998; 12:660-665.
24. Fouque D, Peng SC, Kopple JD. IGF-1 treatment in chronic renal failure: abnormal plasma kinetics. Kidney Int 1995; 47:869-675.
25. Garibotto G, Barreca A, Russo R, Sofia A, Araghi P, Cesarone A, et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99:97-105.
26. Iglesias P, Diez JJ, Fernandez-Reyes MJ, Aguilera A, Burgues S, Martinez-Ara J, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis 1998; 32:454-463.
27. Feber J, Cochat P, Lebl J, Krasnicanova H, Dtephan J, David L, et al. Body composition in children receiving recombinant human growth hormone after renal transplantation. Kidney Int 1998; 54:951-955.
28. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998; 9:2368-2376.
29. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, et al. Immunologic function and survival in hemodialysis patients. Kidney Int 1998; 54:236-244.
30. King AJ, Kehayias JJ, Roubenoff R, Schmid CH, Pareira BJ. Cytokine production and nutritional status in hemodialysis patients. Int J Artif Organs 1998; 21:4-11.
31. Lowrie EG. Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 1998; 32:S105-112. This paper analyses the interrelations between inflammation and nutritional evaluation.
32. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54:627-636.
33. Bistrian BR, McCowen KG, Chan S. Protein-energy malnutrition in dialysis patients. Am J Kidney Dis 1999; 33:172-175. This is a short and clear description of the systemic inflammatory response syndrome and of its nutritional consequences.
34. Ikizler TA, Wingard RL, Sun M, Harvell J, Parker RA, Hakim RM. Increased energy expenditure in hemodialysis patients. J Am Soc Nephrol 1996; 7:2646-2653.
35. Ahmad S, Robertson P, Golper TA, Wolfson M, Kurtin P, Katz LA, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990; 38:912-918.
36. Sakurauchi Y, Matsumoto Y, Shinzato T, Takai I, Nakamura Y, Sato M, et al. Effects of L-carnitine supplementation on muscular symptoms in hemodialyzed patients. Am J Kidney Dis 1998; 32:258-264.
37. Sloan RS, Kastan B, Rice SI, Sallee CW, Yuenger NJ, Smith B, et al. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation. Am J Kidney Dis 1998; 32:265-272.
38. Kopple JD. Dietary protein and energy requirements in ESRD patients. Am J Kidney Dis 1998; 32:S97-104. This reference gives the recognized recommendations on protein and energy requirements in end-stage renal disease.
39. Uribarri J, Leibowit J, Dimaano F. Caloric intake in a group of peritoneal dialysis patients. Am J Kidney Dis 1998; 32:1019-1022.
40. Ross EA, Koo LC. Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients. Am J Kidney Dis 1998; 31:62-66.
41. Aguilera A, Codoceo R, Selgas R, Garcia P, Picornell M, Diaz C, et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998; 13:1476-1483.
42. Sharma K, Considine RV, Michael B, Dunn S, Weisberg LS, Kurnik BRC, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51:1980-1985.
43. Nishizawa Y, Shoji T, Tanaka S, Yamashita M, Morita A, Emoto M, et al. Plasma leptin levels and its relationship with body composition in hemodialysis patients. Am J Kidney Dis 1998; 31:655-661.
44. Johansen KL, Mulligan K, Tai V, Schambelen M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998; 9:1080-1084.
45. Dagogo-Jack S, Ovalle F, Landt M, Gearing B, Coyne DW. Hyperleptinemia in patients with end-stage renal disease undergoing continuous ambulatory peritoneal dialysis. Peritoneal Dial Int 1998; 18:34-40.
46. Stenvinkel P. Leptin - a new hormone of definite interest for the nephrologist. Nephrol Dial Transplant 1998; 13:1099-1101. This paper reviews the main information concerning the actions of leptin, the mechanisms of its elevated serum levels in renal disease and its implications in dialysis patients.
47. Nordfors L, Lönnqvist F, Heimbürger O, Danielsson A, Schalling M, Stenvinket P. Low leptin expression and hyperleptinemia in chronic renal failure. Kidney Int 1998; 54:1267-1275.
48. Kokot F, Adamczak M, Wiecek A. Plasma leptin concentration in kidney transplant patients during the early post-transplant period. Nephrol Dial Transplant 1998; 13:2276-2280.
49. Landt M, Brennan DC, Parvin CA, Flavin KS, Dagogo-Jack S, Coyne DW. Hyperleptinemia of end-stage renal disease is corrected by renal transplantation. Nephrol Dial Transplant 1998; 13:2271-2275.
50. Coyne DW, Dagogo-Jack S, Kein S, Merabet E, Audrain J, Landt M. High-flux dialysis lowers plasma leptin concentration in chronic dialysis patients. Am J Kidney Dis 1998; 32:1031-1035.
51. Kokot F, Wiecek A, Mesjasz J, Adamczak M, Spiechowicz U. Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant 1998; 13:1200-1205.
52. Dagogo-Jack S, Franklin SC, Vijayan A, Liu J, Askari H, Miller SB. Recombinant insulin-like growth factor (IGF-1) therapy decreases plasma leptin concentration in patients with chronic renal insufficiency. Int J Obes Relat Metab Disord 1998; 22:1110-1115.
53. Fouque D, Juillard L, Lasne Y, Tabakian A, Laville M, Joly M-O, et al. Acute leptin regulation in end-stage renal failure: the role of growth hormone and IGF-1. Kidney Int 1998; 54:932-937.
54. Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996; 50:550-556.
55. Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, et al. Nocturnal hemodialysis: the three-year experience. J Am Soc Nephrol 1998; 9:859-868.
56. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9:1285-1292.
57. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54:2207-2217.
58. Foley RN, Parfrey PS, Harnett JD, Kent GM, O'Dea R, Murray DC, et al. Mode of dialysis and mortality in end-stage renal disease. J Am Soc Nephrol 1998; 9:267-276. A meaningful longitudinal survey of the influence of the mode of dialysis on survival.
59. Soucie JM, McClellan WM. Early death in dialysis patients: risk factors and impact on incidence and mortality rates. J Am Soc Nephrol 1996; 7:2169-2175.
60. Jones CH, Newstead CG, Wills EJ, Davison AM. Serum albumin and survival in CAPD patients: the implications of concentration trends over time. Nephrol Dial Transplant 1997; 12:554-558.
61. Aparicio M, Cano N, Chauveau P, Azar R, Canaud B, Flory A, et al. Nutritional status of hemodialysis patients: a French National Cooperative Study. Nephrol Dial Transplant; in press.
62. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 1998; 31:997-1006.
63. Sreedhara R, Avram MM, Blanco M, Batish R, Avram MM, Mittman N. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J Kidney Dis 1996; 28:937-942.
64. Duggan A, Huffman FG. Validation of serum transthyretin (prealbumin) as a nutritional parameter in hemodialysis patients. J Renal Nutr 1998; 8:142-150.
65. Kalantar-Zadeh K, Dunne E, Nixon K, Kahn K, Lee GH, Kleiner M, Luft FC. Near infra-red interactance for nutritional assessment of dialysis patients. Nephrol Dial Transplant 1999; 14:169-175.